| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Tuesday, Eli Lilly And Company (NYSE:LLY) released topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating tirzepatide once weekly for long-term weight management and delay in progression to diabetes in adults with pre-diabetes and obesity or overweight.
Tirzepatide is sold as Zepbound for weight and Mounjaro for diabetes.
Also Read: Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market.
Tirzepatide was evaluated in 1,032 adults who had pre-diabetes at randomization and obesity or overweight for a treatment period of 176 weeks, followed by a 17-week off-treatment period (193 weeks in total).
Results from the SURMOUNT-1 phase 3 study’s primary analysis at 72 weeks in all participants were published in the New England Journal of Medicine in 2022.
In a key secondary endpoint, tirzepatide led to a significant reduction in the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight from baseline to week 176.
For the efficacy estimand, pooled doses of tirzepatide achieved significant results, demonstrating a 94% reduction in risk of progression to type 2 diabetes compared to placebo up to week 176.
For the treatment-regimen estimand, pooled doses of tirzepatide resulted in a significant 93% reduction in risk of progression to type 2 diabetes compared to placebo up to week 176.
In an additional key secondary endpoint, tirzepatide (10 mg and 15 mg) led to statistically significant weight reduction compared to placebo in adults with pre-diabetes and obesity or overweight from baseline to week 176.
For the efficacy estimand, adults taking tirzepatide achieved average weight reductions of 15.4% (5 mg), 19.9% (10 mg), and 22.9% (15 mg) compared to placebo (2.1%) at week 176.
For the treatment-regimen estimand, adults taking tirzepatide achieved average weight reductions of 12.3% (5 mg), 18.7% (10 mg), and 19.7% (15 mg) compared to placebo (1.3%) at week 176.
During the 17-week off-treatment follow-up period, those who had discontinued tirzepatide began to regain weight and had some increase in the progression to type 2 diabetes, resulting in an 88% reduction in the risk of progression to type 2 diabetes compared to placebo.
Price Action: LLY stock is up 2.19% at $942 during the premarket session at last check Tuesday.
Read Next:
Photo by Ciara Kimsey via Shutterstock
Posted In: LLY
